MAM
Bobble AI appoints Ravi Shharma as its chief business officer
Mumbai: Bobble AI on Friday announced the appointment of Ravi Shharma as its new chief business officer. In his capacity as chief business officer, Shharma will be responsible for driving B2B business growth for existing revenue streams – A&M (Advertising & Marketing), DaaS (Data as a Service), and TaaS (Technology as a Service) and future streams, overseeing sales and revenue generation strategies, and exploring new market opportunities to scale revenue. He will work closely with the executive team to steer Bobble AI towards continued success and growth and report to founder & CEO Ankit Prasad.
“We are excited to welcome Ravi to our team. His extensive work experience of around 25 years, proven track record as a sales leader with quite a few Fortune 500 companies, deeper understanding of media sales, ability & vision to scale businesses in a rapidly changing digital landscape and commitment to delivering results will undoubtedly be a great asset to our business going forward. Bobble AI has been roping in industry stalwarts to accelerate the growth and expansion plans and we are confident that Ravi’s integration into the team will strengthen that process & help us achieve new milestones,” said Prasad.
Shharma comes with a solid reputation as a veteran sales leader with a rich and diverse background coupled with exceptional revenue growth skills while working as sales/ revenue head for many global & Indian media companies like CNN, Turner Broadcasting, Cartoon Network, Warner Bros, HBO, Gaana & Saavn in his previous stint. In his more than two decades of experience, he has contributed to an array of activities spanning evolving business strategy and value proposition, creating a multi-year business plan along with the creation of multi-geography business ecosystems.
Having a strong understanding of the entire media landscape – from Print to TV to Digital as an industry stalwart, at Bobble AI he will be instrumental in envisioning, designing and executing impactful business development strategies aligning the company’s expansion plans, its industry vision and the impactful approach backed by exclusive consumer intelligence and artificial intelligence to bring a paradigm shift in the mobile marketing & advertising landscape.
Shharma said, “In the last few years Bobble AI has emerged as the most impactful deep tech solution company in India by re-imagining the keyboard utility as a holistic conversation media platform that has empowered brands to engage with their millions of potential customers in a creative and non-intrusive way. Despite having worked with many global media companies for over two decades, it’s probably the first time I felt moved by the unparalleled disruptions in the mobile marketing & advertising space that Bobble AI is driving and challenging the incumbents. I am quite excited to be part of a visionary team of innovators and look forward to achieving our collective goals and driving the company’s growth.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
